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Summary 
The transforming properties of fibroblast growth factor 3 (FGF-3) were investigated in MCF7 breast cancer cells 
and compared to those of FGF-4, a known oncogenic product. The short form of fgf-3 and the fgf-4 sequences 
were each introduced with retroviral vectors and the proteins were only detected in the cytoplasm of the infected 
cells, as expected. In vitro, cells producing FGF-3 (MCF7.fgf-3) and FGF-4 (MCF7.fgf-4) displayed an amount 
of estrogen receptors decreased to around 45% of the control value. However, MCF7.fgf-3 cell proliferation 
remained responsive to estradiol supply. The sensitivity of the MCF7.fgf-4 cells, if existant, was masked by the 
important mitogenic action exerted by FGF-4. In vivo, the MCF7.fgf-3 and MCF7.fgf-4 cells gave rise to tumors 
under conditions in which the control cells were not tumorigenic. Supplementing the mice with estrogen had the 
paradoxical effect of totally suppressing the start of the FGF-3 as well as the FGF-4 tumors. Tumorigenicity in 
the presence of matrigel was similar for MCF7.fgf-3 and control cells and was increased by estrogen 
supplementation. Once started, the MCF7.fgf-4 tumors grew with a characteristic high rate. Remarkably, FGF-4 
but not FGF-3, stimulated the secretion of vascular endothelial growth factor (VEGF165) without altering the 
steady-state level of its mRNA, suggesting a possible regulation of VEGF synthesis at the translational level in 
MCF7 cells. The increased VEGF secretion is probably involved in the more aggressive phenotype of the 
MCF7.fgf-4 cells while a decreased dependence upon micro-environmental factors might be part of the increased 
tumorigenic potential of the MCF7.fgf-3 cells. 
Key words: FGF-3, FGF-4, MCF-7 breast cancer cells, tumorigenicity, VEGF 
 
Introduction 
The fibroblast growth factors (FGFs) form a family of structurally-related heparin-binding growth factors up to 
20 genes are now identified [1]. Among the 10 gene products well characterized [2-5], FGF-3 to FGF-8 and 
FGF-10 are secreted growth factors. FGF-1, FGF-2 and FGF-9 which lack the classical signal peptide, are 
released from the cell by a mechanism that does not involve the Golgi apparatus. FGFs concentrate in the 
extracellular matrix where the heparan sulfate proteoglycans provide the low affinity binding sites which present 
the FGFs to their high affinity receptors. These receptors are transmembrane tyrosine-kinases that trigger the 
FGF signaling pathways. There are four receptor genes, FGFR-1 to FGFR-4, but alternative splicing generates 
numerous isoforms of the proteins, which each possesses distinct affinities for the FGF ligands (review in [6]). 
In a very characteristic way, the ectopic production of several FGF family members that are not expressed in 
normal adult tissues is involved in mouse mammary tumorigenesis. Fgf-3 has been identified as a main target of 
mouse mammary tumor virus (MMTV) insertional activation in mouse mammary tumors [7]. Fgf-4 is also 
activated in these tumors although much less frequently than fgf-3 [8, 9]. Fgf-4 expression is associated with the 
acquisition of a metastatic phenotype by the tumoral cells [10]. FGF-3, FGF-4 and also FGF-8 specifically 
cooperate with the wnt-1 gene product, to induce the development of mouse mammary tumors ([11] and 
references therein). As models for breast cancer, transgenic mice were produced in which FGF expression was 
targeted to the mammary epithelium by the MMTV promoter. In such model systems, FGF-3 and FGF-7 were 
demonstrated to act as potent proliferative inducers in the mammary gland [12, 13]. 
In human also, deregulation of the genes for FGFs and their receptors might induce autocrine loops and/or 
paracrine interactions and might thus contribute to the processes of mammary cell transformation and mammary 
tumor progression. Indeed, the FGFR-1, FGFR-2 andFGFR-3 genes are amplified in 12.7%, 11.5% and 10% of 
breast cancers, respectively; they are also expressed at high levels in, respectively, 22%, 4% and 32% of the 
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breast tumor samples [14, 15]. Messenger RNAs for fgf-1, fgf-2 are present in all samples of breast cancer; 
whereas mRNA for fgf-5, fgf-6, fgf-7, fgf-8 and fgf-9 are detectable in various percentages of the tumor samples 
[14, 15]. The production of FGF-1 and FGF-2 is down-regulated in the tumoral cells in comparison with normal 
tissue or begnin tumors [16, 17]. In contrast, the fgf-7 expression level measured in the non-malignant breast is 
conserved in the malignant tissue. This FGF-7 is mainly produced by the fibroblasts but could influence the 
progression of breast cancer because of the presence of its specific receptor, FGFR-2 IIIb, on the epithelial cells 
[18]. FGF-3 has not been detected in breast cancer; however, it also binds to FGFR-2 IIIb, so it could induce 
similar disregulation in the mammary tissue growth as do FGF-7 or FGF-10. Moreover, following in vitro the 
progression of the MCF10 cells from immortalization to tumorigenicity, Russo and collaborators have shown 
that fgf-3 amplification and overexpression are early events in the transformation of these human breast epithelial 
cells [19, 20]. 
In previous studies, we demonstrated that fgf-3 expression in a mouse mammary cell line (EF43) confered a 
tumorigenic, invasive and metastatic potential to the cells [21]. We found that FGF-3 exerts a specific effect, 
which differs from the mode of action of FGF-4, a known oncogenic product [22]. The present work was thus 
undertaken to investigate what was the effect of an fgf-3 expression in human mammary cells. MCF7 breast 
cancer cells were chosen, since their low tumorigenicity and the presence of estrogen and progesterone receptors 
[23] are interesting properties to study the progression of breast cancer cells in particular from hormone-
dependence to hormone-independence [24, 25]. The messenger RNA for the four FGF receptor genes are 
detected in MCF7 cells [14, 26]. Thus, it was demonstrated that MCF7 cells that overexpress FGF-1 become 
tumorigenic and metastatic in mice not supplemented with estrogen [27, 28]. In contrast, exposed in vitro to 
recombinant FGF-2, MCF7 cells are significantly growth-inhibited although mitogenic events are concomitantly 
induced [29, 30]. When transfected with, fgf-4, MCF7 cells give rise to progressively growing metastatic tumors 
in untreated or tamoxifen-treated ovariectomized nude mice [31, 32]. 
In the experiments reported here, fgf-3 was introduced into MCF7 cells by means of retroviral vectors and, for 
comparison purposes, we induced fgf-4 expression in MCF7 cells from a construct identical to that carrying fgf-
3. We describe the phenotypic modifications induced in vitro and in vivo by the production of FGF-3 or FGF-4 
in MCF7 cells. Tumoral progression was observed as a result of FGF-3 overproduction as shown by the 
decreased dependence of the tumor take on microenvironmental factors. The in vivo tumorigenic effect of FGF-4 
was, however, more potent, and the specific FGF-4 in vitro properties, i.e. a mitogenic action on MCF7 cells, 
and the stimulation of VEGF production are likely to be involved in the process. 
Materials and methods 
Cell cultures 
The GP+envAm12 packaging cell line [33], received from Genetix Pharmaceuticals (Tarrytown, NY, USA), was 
grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS, Gibco-
Life Technologies, Merelbeke, Belgium), penicillin (102 U/ml) and streptomycin (102 µg/ml). The MCF7 breast 
cancer cell line was cultured in the same medium. Cell cultures were maintained at 37°C in a 5% CO2 
humidified atmosphere. 
Production of retroviral vectors and infection of MCF7 cells 
Three plasmids derived from the Moloney Murine Leukemia virus, were used [21]. The DOBS control plasmid 
carries only the selection gene neo under the control of the SV40 early promoter-enhancer. The DO-fgf-3 and 
DO-fgf-4 plasmids possess, under the viral 5'LTR control, the mouse fgf-3 cDNA and the mouse fgf-4 cDNA, 
respectively. The introduced fgf-3 sequence was the short fgf-3 form. This form starts at the AUG codon 
(whereas the longer form starts at a CUG) and codes for a 31-kDa product that goes into the secretory pathway 
[34]. These constructions were transfected into the packaging GP+envAm12 cells by calcium phosphate 
precipitation to obtain cells producing amphotropic retroviral vectors. Preparation of viruses, titration on 
NIH3T3 cells and infection of MCF7 cells were performed as described [21]. MCF7.C, MCF7.fgf-3 and 
MCF7.fgf-4 cells are geneticin-resistant populations selected in 350 µg active G418 (Gibco)/ml and carrying the 
control empty vector, the fgf-3 and the fgf-4 vectors, respectively. 
Immunofluorescence 
To assess FGF-3 production, cells were grown on cov-erslips, fixed (20 mm at -20°C) in acetone-methanol (v/v), 
permeabilized with 0.2% Triton X-100 in phosphate buffered saline (PBS) for 5min and treated with 1.5% 
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powdered milk in PBS for 30 min at room temperature to block nonspecific binding of the antibodies. The 
coverslips were then exposed (1 h at 37°C) to the 1:300 dilution of a rabbit polyclonal antiserum against FGF-3 
(kindly provided by Dr. C. Dickson, London, UK) and then to a fluoresceine labelled secondary antibody 
(Dakopatts, Copenhagen, Denmark) diluted 1:30 (30 min at 37°C). Detection of FGF-4 production was carried 
on in the same way except that the cells were fixed in absolute methanol and the rabbit anti-FGF-4 anti-serum 
(kindly provided by Dr. C. Dickson, London, UK) was diluted 1:10. After washing, the coverslips were mounted 
with Fluoprep (BioMérieux, Marcy l’Etoile, France) and viewed with an Olympus-Meridian confocal laser scan 
microscope. E-cadherin was detected on cells fixed with methanol at -20°C, using an anti-human E-cadherin 
monoclonal antibody (6F9, Cappel, Organon Tecknica, Turnhout, Belgium) diluted 1:20. Vimentin staining was 
performed on cells fixed in 3% paraformaldehyde and permeabilized in methanol; the antiserum, used at a 1:25 
dilution, was the mouse anti-human vimentin of Monosan-Sanbio (Uden, The Netherlands) 
Proliferation assays 
To compare the in vitro proliferation of the three infected MCF7 cell populations, cells of each type (2.5 x 104) 
were seeded in 24-well plates (Costar). Every two days, samples were sonicated and their DNA content was 
determined by fluorimetry using the bis-benzimidazol H 33258 reagent (Hoechst, S.A, Brussels, Belgium). To 
analyse in vitro the sensitivity to hormonal stimulation, cells (2 x 104) were seeded in quadruplicate in 24-well 
plates and grown for two days in phenol-red-free DMEM medium (Gibco) supplemented with 1% charcoal-
stripped FCS. After 48 h, the medium was changed and the culture was continued in the absence or the presence 
of 10-8 M or 10-9M 17β-estradiol (Sigma) for 6 days. The DNA content in each well was measured as above, and 
the results were expressed as the mean of four determinations ± SD. 
Estradiol and progesterone receptors determination 
Confluent monolayers of the MCF7 cell derivatives (5 x 106 cells per test) were grown in complete medium or, 
during 3 days, in phenol red-free medium supplemented with 10% charcoal-stripped FCS. The cells were 
washed, resuspended in 1 ml PBS, sonicated and centrifuged. Estrogen and progesterone receptors were 
measured on these extracts by a sandwich EIA, using the standard kit supplied by Abbott Laboratories (Chicago, 
Illinois). The results were expressed as a function of the protein amounts present in the extracts and measured by 
a Bradford assay. Each experiment in complete or estrogen-depleted media was repeated twice. 
Western blot analysis of VEGF in conditioned media 
The conditioned media were prepared on cultures of each cell type in 10 cm dishes seeded the day before with         
2 x 106 cells. The cells were washed twice with serumfree medium, incubated with a third washing for 2 h and 
cultured in 6 ml of the same medium for 24 h. After conditioning, the cell number was checked (by counting or 
DNA dosage) for each cell type so that the medium sample analysed corresponded to the same number of cells. 
The conditioned medium was collected, centrifuged to remove cell debris, passed through a 0.22 µm filter and 
stored at 4°C. VEGF detection was performed as described in [35]. In short, 1 ml of conditioned medium was 
dialysed overnight against 100 ml of 200 mM ammonium acetate, lyo-philized, resuspended in 15 µl and 
submitted to 15% SDS-PAGE analysis under non-reducing conditions. Western blotting was performed using a 
1:500 dilution of a polyclonal (AB 1442; Chemicon, Temecula, USA) or a monoclonal (V-4758,  Sigma) 
antibody against recombinant human VEGF165 and, as responsive secondary antibody, peroxidase-conjugated 
swine anti-rabbit IgG (Dako, Copenhagen, Denmark, P0217) or peroxidase-conjugated rabbit anti-mouse IgG 
(Daco, P0260) diluted 1:1000. Peroxydase was revealed by the enhanced chemoluminescence assay (ECL, 
Amersham Corp). When indicated, exogenous FGF-4 (10-100 ng/ml of human recombinant FGF-4; ICN 
160071) was added to the culture medium. 
Quantitative RT-PCR of VEGF165 mRNA 
Total RNA was extracted as described in [35] and RT-PCR was performed on 10 ng of total RNA in a final 
volume of 20 µl using a Perkin-Elmerkit (Foster City, California, USA) and following manufacturer's 
instructions. Reverse transcription was carried out with A274 (5'-CTC ACC GCC TCG GCT TGT CAC A-3') as 
primer during 15' at 70°C. PCR products were generated with A275 (5'-CCT GGT GGA CAT CTT CCA GGA 
GTA-3') as forward primer and A274 as reverse primer. PCR conditions were 95°C/2 min, followed by 29 cycles 
consisting of 94°C/20 s, 66°C/20 s and 72°C/30 s and a final elongation step of 72°C/2 min. The amplification 
product of the RNA coding for the VEGF165 isoform has a 407bp size. To control the efficiency of the RT-PCR, 
we designed a synthetic RNA which can be reverse-transcribed and amplified with the same primers. Four 
thousand copies were added to each sample. The amplification product of this synthetic RNA is 311 bp long. 
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The amplification products were electrophoresed on a polyacrylamide gel, stain with Gelstar (Sanver Tech, 
Antwerpen, Belgium), scanned with a FluorSImager, and analysed using multianalyst software (Biorad, 
Belgium). 
Tumorigenicity in nude mice 
Four- to five-week-old female athymic nude mice (nu/nu Swiss mice from Iffa Credo, L'Arbresle, France) were 
used for in vivo studies. The cells were trypsinized, counted, centrifuged, resuspended in serum-free medium and 
100 µl samples were injected subcutaneously on the back, at the indicated cellular densities. Injections in the 
mammary fat pad gave the same results as subcutaneous implantations. The mice received two injections each 
and 3-5 mice were used per experimental group. Coinjection of cells with matrigel was made as described in [36] 
with 0.70 x 106 cells in 100 µl, mixed with 100 µl matrigel (10 mg/ml, maintained at 4°C). For estrogen 
supplementation, pellets of 1.7 mg 17β-estradiol, 60-day release (Innovative Research of America, Toledo, OH) 
or Silastic capsules containing 1.5 mg estradiol and prepared as described in [36] were implanted between the 
scapulae at the time of injection. The latency period (expressed in days ± SD) was defined as the time between 
injection and appearance of a 4-mm diameter nodule which will continue to grow. Tumor development was 
monitored twice a week by caliper measurements of two diameters and expressed as the mean diameter ± SD. 
Results 
Characterization of the infected MCF7 cell derivatives 
Amphotropic retroviral vectors carrying fgf-3 or fgf-4 or the selection gene alone, were produced and used to 
infect MCF7 cells. The three established G418-resistant populations are referred to as MCF7.fgf-3, MCF7.fgf-4, 
and MCF7.C, respectively. 
Expression of the genes introduced was analysed by immunofluorescence. The MCF7.fgf-3 cells were all stained 
for FGF-3, around 75% of them displayed very strong staining (Figure 1A). The protein was exclusively 
cytoplasmic and it accumulated in the Golgi apparatus, as expected for this short FGF-3 form [34]. Positivity for 
FGF-4 in the cytoplasm of the relevant cells was also very strong (Figure 1B). No obvious difference appeared 
between the staining intensity in the two transfected cell populations. FGF-3 and FGF-4 were not detected in the 
MCF7.C or the parental cells. 
Figure 1: Production of FGF-3 and FGF-4 in the MCF-7 cells infected by the vectors carrying fgf-3 (A) or fgf-4 
(B). Immunofluorescence detection was performed with an anti-FGF-3 antiserum (A) or an anti-FGF-4 
antiserum (B). Under both conditions, MCF-7.C cells were negative. Confocal microscopy. Scale bars = 10 µm. 
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In comparison with the MCF7 cells (control or parental, Figure 2A), the MCF7.fgf-3 and MCF7.fgf-4 cells were 
morphologically modified (Figures 2B and 2C). Their spreading on the culture dish was slowered and their 
adhesion to plastic was decreased. These effects were less pronounced for the MCF7.fgf-3 than the MCF7.fgf-4 
cells which, in addition, were able to form domes. 
Expression of the cell-to-cell adhesion molecule E-cadherin was therefore investigated by immunofluorescence 
staining in the MCF7.fgf-3, MCF7.fgf-4 and the MCF7.C cells. They were all E-cadherin positive and there was 
no apparent difference between the E-cadherin amounts present on the various cell types (not shown). All the 
cells were also negative for vimentin (not shown) indicating that no epithelial-mesenchymal transition had 
occurred (review in [37]). 
Figure 2: Morphology of the MCF-7.C (A), MCF-7.fgf-3 (B) and MCF-7-fgf-4 (C) cells in monolayers on 
plastic. Phase contrast microscopy. Scale bars = 25 µm. 
 
 
In vitro proliferation and hormone sensitivity of the MCF7.fgf-3 and MCF7.fgf-4 cells 
The growth curves of the MCF7-derived cells in complete medium were established by measuring their DNA 
contents every two days. The MCF7.C, MCF7.fgf-3 or MCF7.fgf-4 cells proliferated equally well with a 
doubling time of about 37 h. In a 1%-serum and estrogen-free medium, proliferation of the control was much 
reduced and an increased growth rate was re-established upon addition of estradiol (10-9M, Figure 3) in 
agreement with the hormonal sensitivity of the MCF7 parental cells. The growth response of the MCF7.fgf-3 
cells was very similar to that of the controls (Figure 3) indicating that the cells producing FGF-3 were still 
estrogen sensitive and that the endogenously produced FGF-3 had no mitogenic effect. In contrast, the 
MCF7.fgf-4 cells, highly proliferated in the depleted medium and this growth was not further increased by 
estradiol addition. 
In parallel, we determined whether fgf-3 and fgf-4 expression could modify the amounts of estrogen and 
progesterone receptors in MCF7 cells. The cells were grown in 10% serum with complete or estrogen free-
medium for 3 days and their receptor amount was expressed as a function of the total protein content of the 
cellular extracts. The MCF7.C control cells showed an amount of receptors which agrees with that of the 
parental cells. However, both growth factor-producing cell types showed a lower amount of receptors (as shown 
for a representative experiment in Table 1). When expressed in percentages of the MCF7.C value, the mean 
content in estrogen receptors decreased to 48.8% (± 7.7%) and 41.4% (± 1.1%) forthe MCF7.fgf-3 and 
MCF7.fgf-4 cells, respectively. In contrast, the amounts of progesterone receptors was significantly increased by 
both fgf-3 and fgf-4 expression. 
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Figure 3: Sensitivity to estradiol of the in vitro proliferation of the MCF-7.C, MCT-7.fgf-3 and MCF7.fgf-4 cells. 
The cells (2 x 104) were seeded in 24-well plates in quadruplicate and grown in estrogen-free medium containing 
1% serum. After two days, the medium was changed and the culture continued in the absence or the presence of 
10-9 or 10-8 M 17β-estradiol for 6 days. Cell proliferation was expressed by the mean amount of DNA recovered 
per well ± SD. 
 
 
Table 1 : Estrogen and progesterone receptor determination 
 Receptor amounts in fmol/mg protein
 Estradiol (%) Progesterone 
Complete medium   
MCF7.C 191(100) 6 
MCF7.fgf-3 90 (47) 48 
MCF7.fgf-4 80 (42) 50 
Estrogen-depleted medium  
MCF7.C 422 (100) 3 
MCF7.fgf-3 149 (35) 13 
MCF7.fgf-4 166 (39) 14 
 
Table 2: Tumorigenicity of the MCF7.fgf-3 and MCF7.fgf-4 cells 




 Cell number Estradiol Matrigel   
MCF7.C 2 x 106 - - 0/4 (0) - 
MCF7.fgf-3 2 x 106 - - 5/8 (62) 40 ± 5 
MCF7.fgf-4 2 x 106 - - 6/8 (75) 20 ± 3 
MCF7.C 2 x 106 + - 0/8 (0) - 
MCF7.fgf-3 2 x 106 + - 0/10 (0) - 
MCF7.fgf-4 2 x 106 + - 1/10 (10) 44 
MCF7.C 0.7 x 106 - + 5/8 (62) 56 ± 19 
MCF7.fgf-3 0.7 x 106 - + 5/6 (83) 43 ± 22 
MCF7.fgf-4 0.7 x 106 - + 1/6 (16) 66 
MCF7.C 0.7 x 106 + + 6/8 (75) 25 ± 3 
MCF7.fgf-3 0.7 x 106 + + 8/10 (80) 27 ± 5 
MCF7.fgf-4 0.7 x 106 + + 8/10 (80) 33 ± 7 
*Mean time between injection and appearance of a 4 mm diameter nodule. 
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Tumorigenicity in nude mice 
There are numerous MCF7 sublines which, among other characters, differ in their tumorigenic properties [38]. 
The MCF7 cells used here do not develop tumors in nude mice supplemented with estrogen after subcutaneous 
inoculation, unless the cells are injected with matrigel [36]. To probe a possible effect of FGF-3 production on 
the MCF7 cell tumorigenicity, the MCF7.fgf-3 cells (2 x 106) were first injected in nude mice under conditions in 
which the parental cells are not tumorigenic, i.e. without matrigel nor hormonal supply. As shown in Figure 4, 
the control MCF7.C cells did not give rise to any tumor but the MCF7.fgf-3 cells were tumorigenic with tumors 
developing at five out of the eight injection sites (Table 2). These tumors appeared progressively and grew 
slowly; two of them regressed after 100 days. The MCF7.fgf-4 cells induced tumors at six out of the eight 
injection sites. They appeared simultaneously, grew rapidly and reached a larger volume than the MCF7.fgf-3 
tumors (Table 2, Figure 4). 
Figure 4: Tumorigenicity in untreated nude mice of the MCF-7.fgf-3, MCF-7.fgf-4 and MCF-7.C cells, as 
indicated. The cells (2 x 106) were injected subcutaneously at day 0 and the mice examined twice a week for 
tumor appearance and measurement. Tumor growth was expressed by the tumor mean diameter ± SD. 
 
The hormonal influence on the tumor development was then tested for both cell types. In mice that received 
estradiol, the tumor take from the MCF7.fgf-3 cells was totally inhibited (Table 2). The tumorigenicity of the 
MCF7.fgf-4 cells was also strongly reduced since only one tumor appeared after a long 40-day latency period; its 
growth, however, was very fast (Figure 6). 
We also looked for the tumorigenicity of the MCF7 cell derivatives under conditions used previously to induce 
tumors with the parental MCF7 cells [36], i.e. subcutaneous co-injection of a lower number of cells (0.7 x 106) 
and matrigel. In that case, tumors developed from the MCF7.fgf-3 cells with a frequency and a growth rate 
similar to those of the control cells (Table 2, Figures 5A and 5B). The response of the MCF7.fgf-4 cells was very 
different: only one tumor appeared after a long latency period but, once started, it grew very rapidly (Figure 6). 
The influence of an hormonal supplement on tumorigenicity in the presence of matrigel was then investigated. In 
mice receiving estradiol, the MCF7.fgf-3 cell-induced tumors grew much more rapidly than those observed in 
untreated mice (Figures 5 A and 5B). The tumor take was better (around 80%, Table 2) and all the tumors 
appeared after 3 weeks. Hence, the cells expressing fgf-3 give rise to tumors whose growth remains influenced 
by the hormonal level in the animal as the tumors originating from MCF7.C cells. The results also suggest that 
coinjection with matrigel might reverse the hormonal inhibition of the MCF7.fgf-3 tumor take. Similar results 
were obtained with the MCF7.fgf-4 cells (Table 2, Figure 6). 
Analyses of VEGF production 
As described above, the MCF7 cells variants had an increased tumorigenicity. In particular, the tumors formed 
by the cells expressing FGF-4 were characterized by their very rapid growth (Figure 6). Since it is known that 
angiogenesis is a necessary process for tumor development, we looked for the presence of VEGF, a very potent 
angiogenic factor, in the culture medium conditioned by the same number of each cell type. Western blotting 
analyses with an anti-VEGF165 antibody revealed the presence of a 43 kDa faint band in the conditioned media 
from the control cells corresponding to an endogenous VEGF production by the MCF7 cells (Figure 7B). While 
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similar results were obtained with the medium of the MCF7.fgf-3 cells, analysis of the MCF7.fgf-4 cell 
conditioned medium demonstrated a significant stimulation of VEGF production (Figure 7B). This observation 
was supported by adding exogenous human recombinant FGF-4 to cultures of MCF7.C cells at a concentration 
of 10 ng/ml for 2 days. Under such conditions, increased VEGF amounts were detected in the corresponding 
conditioned medium (Figure 7A) suggesting that VEGF synthesis was up-regulated by FGF-4 through an 
autocrine loop, a process which did not occur with the endogenously produced FGF-3.  
Analyses of VEGF165 mRNA expression were performed in MCF7.C, MCF7.fgf-3 and MCF7.fgf-4 cells using 
quantitative RT-PCR. No difference appeared in the steady-state level of VEGF165 mRNA between the three cell 
types (Figure 8), whereas by applying the same technique to mouse mammary FGF-4 producing cells [35], an 
increase of VEGF164 mRNA steady-state level was obtained as compared to the control cells (data not shown). 
This indicates that synthesis of VEGF might be under the control of different regulatory mechanisms depending 
upon the cell type examined. 
Figure 5: Growth curves of tumors formed after subcutaneous injection of MCF7.fgf-3 (A) or MCF7.C (B) cells 
mixed with matrigel. The cells (0.7 x 106) were injected subcutaneously with 1 mg of matrigel at day 0 in animals 
receiving or not an estradiol supplement. The mice were examined twice a week for tumor appearance and 
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Figure 6: Growth curves of tumors developing from the MCF-7.fgf-4 cells. The cells were first injected (2 x 106) 
in untreated mice (mean diameter of n = 6 tumors) or in mice supplemented with estradiol (n = 1 tumor); they 
were also injected (0.7 x 106 ) in the presence of matrigel in untreated mice (n = 1 tumor) or in estradiol 
supplemented mice (mean diameter of n = 8 tumors). 
 
Discussion 
In the present work, we demonstrated that endogenous fgf-3 expression increases the tumorigenic potential of 
MCF7 cells. However, in terms of tumor progression, the FGF-3 producing cells are less aggressive than the 
FGF-4 producing cells. 
In previous reports, the data concerning FGF-3 effect on human [39, 40] and murine [41] mammary cells were 
all obtained by expressing a construct in which a mouse immunoglobulin signal peptide sequence was linked to 
the fgf-3 coding sequence, under the control of the β-actin promoter [42]. This fusion protein was better secreted 
and more active in proliferation tests than the product of the construct used here. In our case, the fgf-3 sequence 
with its endogenous signal peptide was introduced into MCF7 cells under the transcriptional control of the 
retroviral LTR, resulting in a larger expression level of the normal product. Assessing that FGF-3 acts through an 
extracellular loop as FGF-4 does [43], the way FGF-3 is secreted could be a limiting factor for its oncogenic 
action. FGF-3 remains also tightly bound to the extracellular matrix components [44], another factor decreasing 
its availability for the cells. However, MCF7 cells could secrete proteolytic enzymes able to mobilize the growth 
factor [45]. At this point of our study, we consider these factors as part of the specific mechanism of action of 
FGF-3. 
In vitro properties 
We show here that the endogenous production of both FGF-3 and FGF-4 modifies the cell morphology. It also 
reduces by 50% the amount of estrogen receptors of MCF7 cells in comparison with either the parental cells or 
the control transfectants. These two phenotypic modifications are also observed in MCF7 cells that overexpress 
the growth factor heregulin, following transfection with the HRG gene [46] and are consistent with the 
progression of these cells towards a more hormone-independent phenotype. Our results contrast with recently 
published data [47] where the downregulation of ER was not observed in MCF7 clones isolated after transfection 
of the fgf-1 or the fgf-4 gene. The influence of the cellular clone transfected has to be investigated further in this 
respect. 
Despite the reduced receptor number, the MCFl.fgf 3 cell proliferation is stimulated by the addition of estradiol 
to a depleted medium. With our experimental materials (as stated above), no mitogenic effect of FGF-3 was 
observed on MCF7 cells. Using their fusion protein, Basolo et al. [39] reported that fgf-3 expression had a 
growth-stimulatory effect and induced anchorage-independent growth in MCF-10A cells. In contrast, we 
observed a very significant mitogenic action of FGF-4 on MCF7 cells that might mask a possible growth 
stimulatory effect of the estradiol supply. As reported by McLeskey et al. [31], both the proliferation rate and the 
colony formation in soft agar of the MCF7 cells producing FGF-4 were stimulated by estrogen and inhibited by 
tamoxifen indicating that their MCF1.fgf-4 cells have kept in vitro, the hormonal sensitivity of the MCF7 cells. 
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Figure 7: Up-regulation of VEGF synthesis. VEGF production was analysed by Western blotting as described in 
Materials and methods, using in A, the AB1442 anti-VEGF antiserum and in B, a monoclonal anti-VEGF 
antibody (V-4758): conditioned medium of the MCF-7.C cells (lines 1 and 4 in A, line 1 in B), of the MCF7.fgf-3 
cells (line 2 in A and B), of the MCF7.fgf-4 cells (line 3 in A and B), of the MCF7.C control cells cultured with 
10 ng/ml of human recombinant FGF-4 (line 5). As a positive control, 20 ng of human recombinant VEGF165 
were loaded in line 6. The V-4758 monoclonal anti-VEGF was more sensitive and revealed the weak endogenous 
VEGF production by the control and the fgf-3 carrying cells. 
 
In vivo properties 
The parental MCF7 cells used here do not develop tumors after subcutaneous or mammary fat pad inoculation in 
nude mice supplemented with estrogen. Tumors, however, are induced when cells are injected with matrigel,   an 
EHS ('Engelbreth Holm Swarm') tumor extract rich in basement membrane proteins [36]. This tumor take 
appears to be hormone-independent but the subsequent tumor growth is hormone-responsive. Coinjection with 
primary human fibroblasts also increases the tumorigenicity of these MCF7 cells and both matrigel and 
fibroblasts exert cumulative effects [48] showing that the tumor take process is very sensitive to 
microenvironmental factors. It was found in the present work that the MCF7.fgf-3 cells gave rise to tumors under 
conditions where the parental and control MCF7 cells were not tumorigenic. This observation demonstrates that 
an endogenous production of FGF-3 leads the MCF7 cells one step further in the transformation process, making 
them more independent from their environment. In this assay, our MCF7.fgf-4 cells are highly tumorigenic since 
the induced tumors reach a large volume very rapidly. McLeskey and collaborators [31] already reported that  
fgf-4 overexpression in MCF7 cells resulted in cell lines that progressively formed growing tumors in untreated 
or tamoxifen-treated ovariectomized nude mice. These tumors were also shown to form micrometastases [32]. 
The effects of an FGF-1 overproduction were also studied in MCF7 cells: the fgf-1 transfectants were 
tumorigenic in nude mice, the tumors were growing even in the presence of tamoxifen and they were metastatic. 
Their phenotype is, however, distinguishable from that of the tumors formed by the FGF-4-producing MCF7 
cells [27]. 
A striking feature in our tumorigenicity assays is that an estrogen supply suppresses the tumor formation induced 
by MCF7.fgf-3 and MCF7.fgf-4 cells. This paradoxical effect was already seen by McLeskey et al. [31] with 
FGF-4-producing MCF7 cells. Recently this suppressing effect also appeared in the experiments on the 
tumorigenicity of the FGF-1-producing MCF7 cells [27]. The mechanism responsible for this behaviour remains 
unexplained but the combined action of estrogen stimulation and the activation of some FGF signaling pathway 
might generate growth inhibitory conditions [27, 29, 49]. Alternately, the MCF7 transfectants might be more 
sensitive towards 2-methoxyestradiol, an endogenous estrogen metabolite which is cytotoxic for human breast 
cancer and possesses antiangiogenic properties [50,51]. 
In the presence of matrigel, slowly growing tumors appear in untreated mice injected with MCF7.fgf-3 cells and 
an estrogenic supply markedly increases the tumor growth rate. Similar tumorigenicity is observed for the 
MCF7.C cells and was reported for the parental cells [36]. Thus, the FGF-3 tumors develop more rapidly as a 
result of estrogen addition; also injection of a lower cell number with matrigel protects somehow the tumor take 
from the estrogen inhibitory effect. For an unknown reason, matrigel alone did not allow the MCF7.fgf-4 cells to 
grow except in one case and after a long latency. Rapidly growing tumors, however, reappeared when MCF7. 
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fgf-4 cells were implanted with matrigel in estrogen supplemented animals. The mechanisms operating in the 
modulation of the tumor take by matrigel and estrogens need further investigations. 
Figure 8: Expression of VEGF165 mRNA. (A) mRNAfor VEGF165 was measured by RT-PCR in MCF7.C, MCF7 
fgf-3 and MCF7.fgf-4 cells. Lanes 1-3, MCF7 cells; lanes 4—6, MCF7.fgf-3 cells; lanes 7-9, MCF7.fgf-4 cells; 
lane 10, negative control (no template); M = molecular marker (Gibco-BRL). 28S served as an internal control 
for RNA expression. CTR1 and CTR2 are synthetic RNA used to control the efficiency of RT-PCR for VEGF165 
and 28S, respectively. (B) Quantification of VEGF165 expression in the gel shown above (as described in 
methods). Band intensities of amplification products were quantitatively analysed and ratios: VEGF165 RT-PCR 
amplification product/corresponding CTR, were determined. Expression of VEGF165 was normalized to that of 
28S. AU = arbitrary unit. 
 
Increased of VEGF production 
Angiogenesis is a key factor for local tumor invasion and metastasis [52]. FGF-1 and mainly FGF-2 are known 
to be potent angiogenic factors. In contrast, FGF-4 did not appear to exert any direct effect on this process [53]. 
However, we recently demonstrated that FGF-4 is a potent indirect angiogenic factor in mouse mammary cells 
since it stimulates VEGF expression both at the mRNA and the secreted protein levels [35]. VEGF is a major 
angiogenic factor which directly acts on endothelial cells, its role in tumorigenesis is largely documented. 
Inhibition of VEGF action suppresses tumor growth in vivo [54] and high VEGF expression correlates with a 
poor prognosis for human primary breast cancers [55]. Here, we show that the VEGF production by MCF7 cells 
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is up-regulated by the endogenously produced mouse FGF-4 and by the exogenous human recombinant FGF-4 
added to the control cells. We found, however, that the steady-state level of the VEGF165 mRNA remains 
unmodified in the MCF7.fgf-4 cells. This result contrasts with the mechanism of FGF-4 action observed in the 
mouse mammary tumor cells and indicates that VEGF production might be under post-transcriptional control in 
the MCF7 cells. At the end of our experimental work, there appeared a report confirming that MCF7.fgf-4 cells 
have no increased amounts of VEGF mRNA [56]. The authors did not report the level of expression of the 
protein. 
In contrast to the MCF7.fgf-4 cells, the FGF-3 producing MCF7 cells failed to enhance VEGF secretion. 
In conclusion, we have shown that FGF-3 producing MCF7 cells are tumorigenic under conditions where the 
control cells do not give rise to tumors. FGF-3 and FGF-4 share common activity pathways since they both 
down-regulate the estrogen receptor level and since the tumor take from both cell types is inhibited in mice 
supplemented with estrogen. Production and secretion of FGF-4 confer to the cell growth advantage in vitro and 
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